Background: Treatment adherence is an important medical and pharmaco-
| INTRODUCTION
Systemic sclerosis (SSc) is a rare, disfiguring and severe autoimmune connective tissue disease associated with high morbidity and mortality.
It is marked by progressive fibrosis of the skin, joints and internal organs, and is commonly subdivided into two disease subsets based on the extent of skin involvement: limited cutaneous SSc (lcSSc) with skin thickening only distal to elbows and knees, and diffuse cutaneous SSc (dcSSc) with skin thickening extending more proximally or involving the thorax or abdomen (Gabrielli, Avvedimento, & Krieg, 2009; Khanna et al., 2017) . LcSSc occurs more frequently than dcSSc (60% versus 40%) (Meier et al., 2012) and women are more frequently affected than men (female/male ratio: 3/1) (Chifflot, Fautrel, Sordet, Chatelus, & Sibilia, 2008) . Clinical presentation, disease progression and prognosis are highly variable among SSc patients. This disease imposes a considerable burden on a patient's life and interferes with their professional and social life, by causing work interruption, sick leave and financial problems (Hromadkova, Soukup, Cermakova, & Vlcek, 2012) . Despite extensive research efforts, the aetiology and pathogenesis of SSc remain enigmatic. As such, causal or curative therapy is still lacking and the current treatment focuses on symptom control and the slowing of progression towards organ damage and failure. Medical treatment comprises steroids, immunosuppressive agents (methotrexate, mycophenolate mofetil, cyclophosphamide) and symptomatic medication, such as proton pump inhibitors (PPIs) for heartburn, calcium channel blockers (CCBs) for Raynaud's phenomenon and analgesics.
Medication-taking behaviour can be described using several related terms (compliance, adherence, concordance), all different in interpretation (Chakrabarti, 2014; Hill, 2005) . Compliance, considered as the degree to which patients take the prescribed medication, implies a paternalistic view, with patients simply following medical recommendations. Adherence emphasizes patient participation in making treatment decisions. Concordance stresses the concept of shared decisionmaking. In the present study, "adherence" was used to describe the medication-taking behaviour of patients, as recommended by Horne and colleagues (Horne, Weinman, Barber, & Elliott, 2005) .
Adherence determines, to a large extent, the success rate and efficacy of a treatment. It has become increasingly important in medicine owing to growing numbers of chronic diseases, comorbidity, polypharmacy and ageing people. The correct assessment of adherence and the identification of factors contributing to poor adherence can optimize therapeutic decisions and patient management. Factors influencing treatment adherence can be categorized into different groups: demographic, clinical and psychological. Demographic and clinical factors have been investigated more extensively than psychological factors. However, ideas about the necessity of treatment and concerns about treatment have been shown to be associated with adherence and non-adherence in patients with psychological, rheumatic and lung diseases (Verhoef et al., 2014) .
Poor adherence results in increased morbidity, mortality and reduced quality of life. It also causes medical costs owing to therapy escalation and hospitalization, and therefore has an impact on public health costs. The World Health Organization has stated that an improvement in adherence to existing medications would bring more health benefits than the development of new drugs (Ingersoll & Cohen, 2008) . Treatment adherence is a complex, yet highly relevant subject for medical, paramedical, economic and psychological research, and a target for intervention. Additionally, the lack of uniformity across study populations and the variety of definitions and measurements of treatment adherence make it difficult to compare the literature on this topic.
Data on treatment adherence in SSc are scarce, and the limited available evidence suggests a lower degree of treatment adherence compared with that for other rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (Hromadkova et al., 2012; Iudici, Russo, Mitidieri, Cuomo, & Valentini, 2015) .
The aim of the present work was to assess treatment adherence in patients with SSc and evaluate potential associated factors.
| PATIENTS AND METHODS

| Patient recruitment
All patients included in the Belgian Systemic Sclerosis Cohort (BSSC) and under the care of the department of rheumatology at the University Hospital of Leuven were considered for participation in the study. The BSSC is a Belgian multicentre, prospective cohort including SSc patients who fulfil the American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria for SSc (De Decker et al., 2018; Vanthuyne et al., 2009 ). Data on disease activity and organ involvement are collected at baseline, at 6 months and yearly thereafter.
Yearly follow-up includes history, clinical examination and technical investigations, including biochemical analysis, an electrocardiogram (ECG), a chest X-ray, pulmonary function testing (PFT), a 6-min walking test and a transthoracic echocardiogram (De Decker et al., 2018) .
The study was approved by the research ethics committee at University Hospitals/KU Leuven and considered to be in accordance with the Declaration of Helsinki.
Patients who were not taking any medication, lost to follow-up (defined as not visiting a rheumatologist in the last 18 months) or deceased were excluded. All eligible subjects received a letter with introductory information, an informed consent form, a personalized medication overview, and accompanying questionnaires and supplementary questions.
Patients were able to update their individual medication overview if it had been changed-i.e. changes concerning drug dose or frequency, new medication or stopped medication-in the period between the last consultation and the moment of participating in the study. After 1 month, a reminder was sent to nonresponding patients.
Demographic characteristics, such as age, gender, education, employment situation and living situation, were provided by the patient.
The following disease characteristics were retrospectively collected from medical records: SSc subtype, autoantibody profile, disease duration (defined as time of onset of the first non-Raynaud's phenomenon), disease activity score (DAS) and internal organ involvement.
Disease activity was evaluated by the recent EULAR Scleroderma
Trial and Research Group (EUSTAR) DAS index, a weighted 10-point activity index based on skin changes, digital ulcers, modified Rodnan Skin Score, tendon friction rubs, C-reactive protein level and predicted diffusing capacity of the lung for carbon monoxide (DLCO) value. A cut-off score of ≥2.5 indicates active disease (Valentini et al., 2017) .
| Questionnaires
Self-report questionnaires were used to measure treatment adherence and determine the influencing factors. Completing these three questionnaires takes around 45-60 min (CQR: 10-12 min, BMQ-S:
5-8 min, IPQ-R: 30-40 min).
| CQR
The CQR was created to investigate treatment adherence with antirheumatic drug therapy (de Klerk, van der Heijde, van der Tempel, & van der Linden, 1999) . It consists of 19 statements, rated by patients on a four-point Likert scale, ranging from "don't agree at all" (scored as 1) to "fully agree" (scored as 4) (de Klerk et al., 1999) . The 19 statements focus on different topics: trust in the rheumatologist ("I take my medicines because I have complete confidence in my rheumatologist"), attitude towards their medication ("I definitely don't dare to miss my medications"), expectations of the therapy ("I don't expect miracles from my medicines"), reasons for taking or not taking medication ("I take my medicines because I then have fewer problems" or "When I am on vacation, it sometimes happens that I don't take my medicines") and practical tools for taking medication ("I use a dose organizer for my medications").
By adding up the scores for each statement and recoding the statements asking for a negative response (statements 4, 8, 9, 11, 12 and 19), a total summed CQR score can be calculated, as an estimate of adherence (ranging on a continuous scale from "0 = non-adherence" to "100 = perfect adherence"). However, this total summed score showed no correlation with treatment adherence, measured using an electronic medication event monitoring system (MEMS) device, which is considered as the gold standard for assessing adherence (de Klerk, van der Heijde, Landewé, van der Tempel, & van der Linden, 2003) .
It was only validated with the self-reports of patient adherence (a surrogate gold standard) with a specificity of 67% (de Klerk et al., 1999) .
When all statements are weighted without recoding, a discriminant function calculator determines a weighted CQR score. This score has a proven sensitivity of 62% and a specificity of 95% to detect adherence ≤80%. It has been validated against a MEMS device (de Klerk et al., 2003) . It accurately predicts adherence rates and can discriminate between good and poor adherence. The CQR is the only questionnaire validated to measure treatment adherence in patients suffering from rheumatological diseases.
The arbitrary cut-off of 80% is generally accepted in adherence research, which translates to a patient taking at least 80% of the prescribed medication (de Klerk et al., 2003; Hromadkova et al., 2012; van den Bemt et al., 2011) . The CQR was provided by the original Dutch developers, including the Excel worksheet to calculate weights and critical cutting scores.
| BMQ-S
The BMQ evaluates the beliefs that patients have about their medication by questioning treatment necessity and concerns (Horne, Weinman, & Hankins, 1999) . We used BMQ-S to detect factors determining intentional non-adherence to prescribed medication. This questionnaire consists of five items aimed at evaluating the perceived need of medication and five items aimed at evaluating concerns about medication, such as possible side effects or risk of dependence. Each statement is scored on a five-point Likert scale, ranging from "don't agree at all" (scored as 1) to "fully agree" (scored as 5). These scores are summed, separately for necessity and concern items, resulting in one total necessity score and one total concern score, both ranging from 5 to 25. A higher score reflects higher levels of necessity or concern, respectively. Finally, a differential score was calculated by subtracting the total concern score from the total necessity score (range -20 to 20)-the higher the differential score, the higher the necessity; the lower the differential score, the higher the concerns.
The Dutch version of the BMQ-S consists of six necessity items, so the necessity score was divided by six and multiplied by five to get the total necessity score (Verhoef et al., 2014) . Based on both scores, patients can be divided into four attitudinal patient profile groups: accepting (high necessity, low concerns), ambivalent (high necessity, high concerns), indifferent (low necessity, low concerns) and sceptical (low necessity, high concerns) (Iudici et al., 2015) . High and low scores were defined as similar to or above the scale midpoint, and below the scale midpoint, respectively (i.e. ≥15 or <15) (Zwikker, van Duimen, den Broeder, van den Bemt, & van den Ende, 2014) .
| IPQ-R
To determine illness perceptions, defined as the cognitive representations and ideas that people have about their disease, the IPQ-R was used (Moss-Morris et al., 2002) . Illness perceptions contribute more to physical and mental health in SSc patients than classical disease characteristics .
The IPQ-R consists of three dimensions: illness identity, illness perception subscales and causal attributions.
Illness identity-defined as matching symptoms to a disease-is determined by asking patients if they experience certain symptoms and whether they think these symptoms are associated with their disease. We used a questionnaire adapted for SSc, in which nine additional items were added to the 14 standard items .
Twenty-three symptoms were questioned and each scored as "1" if the patient considered them to be disease associated. The higher the total sum, the stronger the belief that symptoms or complaints are related to the disease and thus the higher the illness identity.
The second part of the IPQ-R comprises seven illness perception subscales-timeline acute/chronic, timeline cyclical, consequences, personal control, treatment control, illness coherence and emotional representations-divided over 38 items. Patients have to specify if they agree or disagree with the statements on a five-point Likert scale, from 1 ("strongly disagree") to 5 ("strongly agree"). For each subscale, the ratings were summed.
The third and last part of this questionnaire determines causal attributions. Patients were asked their opinion about possible causes of their disease. The causal attributions are grouped into four subcategories: psychological attributions, immunity disturbances, external risk factors and accident/bad luck/chance. For the illness perception subscales, statements were scored on a five-point Likert scale, from 1 ("strongly disagree") to 5 ("strongly agree") and the scores were summed per subcategory. Finally, participants could also report, in their own opinion, the three most important causes for their disease.
| Supplementary questions
All patients were able to score the degree to which they thought they took their personal medication, as a subjective estimation of treatment adherence, ranging from never (scored as 1), sometimes (scored as 3)
to always (scored as 5).
Finally, patients were asked to answer separate questions about medication preparation, the medication leaflet and fearing medication.
| Statistical analysis
For two-group comparisons involving binary data, we used the chisquare test. Comparisons involving continuous data were performed using an independent-sample t-test, with p = 0.05 and 95% confidence intervals, if normal distribution of variables existed, and the Mann-Whitney U test in other cases. Mean and standard deviation (SD) were used to express continuous data. SPSS version 25 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis.
3 | RESULTS Figure 1 shows the flowchart of patient recruitment. Eighty patients returned their questionnaires, reflecting a 66.7% response rate. The data from sixty-six patients were eligible for analysis.
| Patient characteristics
Demographic and clinical variables of the included patients are presented in Table 1 . The mean number of drugs prescribed specifically for the treatment of SSc (steroids and/or immunosuppressive agents and/or symptomatic therapy) was 2.96.
| Results of CQR -BMQ -IPQ-R
Forty-seven patients (71.2%) had a weighted CQR score of ≤80% (considered as "poor adherence") and 19 patients (28.8%) had a weighted CQR score of >80% (considered as "good adherence"). We also calculated the total summed CQR score to allow for comparison with previously published studies. The mean summed CQR score was 80.5 (range 54.4-100). Twenty-nine patients (43.9%) had a summed score ≤80 and 37 patients (56.1%) >80.
Mean BMQ necessity, concern and differential scores are represented in Table 1 . The scale midpoint for necessity and concern scores was 15. Only two patients had a negative differential score (reflecting higher concern beliefs than necessity beliefs), and two other patients had a differential score of zero. Figure 2 shows patients grouped according to their necessity and concern scores in four attitudinal patient profile groups. Only three patients (4.5%) had a low necessity score (<15).
Results from the IPQ-R, represented by dimension, are depicted in Table 1 . Four IPQ subscales were not completed by all patients, which is made clear by "n = 63" in Table 1 . All participants were able to provide, in their own opinion, the three most important causes of their disease. The most frequently reported causal attributions are listed in Table 2 . A few patients mentioned cold temperature (five patients; 7.6%), smoking (three patients; 4.5%), emotions (six patients; 9.1%) and lack of knowledge about SSc by their physician (two patients; 3.0%).
| Supplementary questions
Most patients stated that they always took all their medication (60 patients; 90.9%). Six patients (9.1%) admitted taking their medication only "sometimes". These cases concerned symptomatic medication:
PPIs in three cases, CCBs in two cases and angiotensin-converting enzyme (ACE) inhibitors in one case.
The results of the questions about medication preparation, the medication leaflet and fearing medication, completed by 65 patients (98.5%), are shown in Table 2 .
| Subgroup analysis
No statistically significant differences were observed between adherent and poorly adherent patients with regard to demographic factors (age, sex ratio, educational status, living situation) or clinical variables (see Table 1 ). For current treatment, no substantial differences were observed between the groups. BMQ-S scores (necessity, concern and differential scores) and patient profile groups were very similar for the adherent and poorly adherent groups. The three patients with low necessity scores were all considered to be poorly adherent. All adherent patients had high necessity scores (see Figure 2 ).
Illness identity scores were numerically higher in the poorly adherent group (11.6) than in the adherent group (10.0); however, the differences did not reach statistical significance (p = 0.177).
Regarding the IPQ subscales, a statistically significant relationship was observed between treatment adherence and the subscale 'timeline acute/chronic' (p = 0.042). No differences between the groups Disease duration (years), mean ± SD 9 ± 8.7 9.7 ± 9.8 7.4 ± 4.6 0.337 † DAS, (n = 53), mean ± SD 1.6 ± 1.2 1.7 ± 1.2 (n = 41) 1.3 ± 0.9 (n = 12) 0.247 † 
Internal organ involvement
IPQ-R
-Illness identity (n = 66), mean ± SD, (range) 11.1 ± 4.3, (0-21) 11.6 ± 4. Table 2 .
| DISCUSSION
The aim of the present study was to determine treatment adherence in patients with SSc and to evaluate potential risk factors. We detected low adherence rates in SSc patients, measured by the CQR.
We could not identify a demographic or clinical factor significantly associated with good or poor adherence. Only one psychological variable, the IPQ subscale "timeline acute/chronic", was significantly associated with treatment adherence (p = 0.042). This subscale assesses the patient's view about how long they think their disease will last.
Poorly adherent patients had a significantly higher score, reflecting a correlation between poor adherence and the belief that the disease would be chronic, without improving over time. Among SSc patients, it has been demonstrated that higher scores on this subscale are associated with younger age, longer disease duration, stronger illness identity, less treatment control and more disease-associated symptoms 
FIGURE 2
Attitudinal patient profiles based on Beliefs about Medicines Questionnaire (BMQ)-necessity and -concern scores: accepting (high necessity, low concerns), ambivalent (high necessity, high concerns), indifferent (low necessity, low concerns) and sceptical (low necessity, high concern) (Richards et al., 2003) . To the best of our knowledge, no relationship between this subscale and treatment adherence in SSc has been described to date. Among other diseases, the relationship between beliefs about having a chronic disease and treatment adherence has been investigated, but with contradictory results. In arterial hypertension, diabetes or sickle cell disease, such beliefs were associated with better adherence (Aflakseir, 2012; Hemphill, Ann, Stephens, Rook, & Franks, 2014; Oudin & Gay, 2017) ; for heart failure, they were associated with lower adherence to ACE inhibitors (Molloy et al., 2009 ).
Among stroke patients or those with bipolar disorder, no relationship could be found between these beliefs and adherence to medication (Averous, Charbonnier, Lagouanelle-Simeoni, Prosperi, & Dany, 2018; Crayton et al., 2017) . Beliefs surrounding the timeline of chronicity are strongly related to beliefs about the seriousness of an illness (Moss-Morris et al., 2002) , which can explain a sense of severity and better adherence. Nevertheless, low expectations for any disease improvement and taking long-term medication for a chronic disease are limiting factors for adherence.
According to the weighted CQR-score, 71.2% of our study population was poorly adherent (adherence of <80%). However, the majority of patients still stated that they always took all of their medication.
The discrepancy of a high subjective estimation of adherence and a low measured adherence is striking. Although the CQR does not precisely measure the amount of prescribed medication taken by the patient, it has proven accurately to predict treatment adherence with a high specificity. This discrepancy was also detected in other studies-for example, in RA patients treated with disease-modifying antirheumatic drugs (DMARDs) (van den Bemt et al., 2011) .
The high subjective estimation of adherence in our study was also accompanied by high medication necessity scores and rather moderate concern scores. This positive attitude towards medication can be explained by medication-related symptom relief. Patients were able to clarify their remarks in a free text box, and the most frequent statement was: "I take my medication, otherwise I feel more symptoms".
This perceived symptomatic benefit and the large proportion of symptomatic medication use in our study might explain this high perceived necessity.
Low necessity scores were only seen among poorly adherent patients, but we did not find a statistically significant relationship between medication beliefs and adherence. Nevertheless, high necessity is generally related to high adherence, as demonstrated in psychiatric disorders (Emilsson, Gustafsson, Öhnström, & Marteinsdottir, 2017) , RA (Zwikker et al., 2014) and cardiac diseases (Byrne, Walsh, & Murphy, 2005) , and high concerns to low adherence, in diabetes (Aflakseir, 2012) . In SSc, Iudici et al. (2014) proved that highly adherent patients have higher necessity-concerns differential scores.
In cardiovascular diseases, beliefs about medication are associated with the need for information and counselling (van Geffen et al., 2012) . Patients receiving information have a more positive view on medication (better necessity-concerns differential score) and better adherence (Clifford, Barber, Elliott, Hartley, & Horne, 2006) . Personal beliefs about a disease and medication are important factors for adherence. Therefore, detecting low necessity beliefs and subsequently starting education and counselling by a multidisciplinary team of physicians, physiotherapists, occupational therapists, rheumatology nurses and psychologists may be a good strategy to improve treatment adherence.
Fearing medication and fearing side effects are an important issue for treatment non-adherence (Harrold & Andrade, 2009 ). Among hypertension, diabetes and atopic dermatitis patients, this is significantly associated with poor adherence (Al-Ramahi, 2015; Patel & Feldman, 2017; Shiyanbola, Brown, & Ward, 2018) . Hromadkova et al. (2012) , in line with our study, could not detect this association in SSc patients.
We even found relatively more fearing people among adherent patients (33.3%) than among poorly adherent patients (14.9%).
Available data on treatment adherence in SSc are scarce and only a limited number of articles have been published over the past decade (Hromadkova et al., 2012; Iudici et al., 2015) . A Czech study from 2012 investigated a small group of 41 SSc patients, of whom only 42% had a good adherence rate, assessed by a CQR score ≥80 (Hromadkova et al., 2012) . The authors did not find a relationship between adherence and demographic or clinical characteristics, and could not identify risk factors for non-adherence. In our opinion, the study used the total summed CQR score, expressed both as a continuous (range 0-100) and a dichotomous (cut-off value of 80%) value, instead of the weighted CQR score (cut-off of 80%). Nevertheless, we shared the same objectives and used similar methods, allowing for comparison between that study and our own. Based on the total summed CQR score, adherence rates in our study were higher (56.1% with a continuous score >80). We observed no difference in general patient characteristics between our study and the Czech study but did observe differences in medication use. Our patients received relatively more symptomatic treatment, such as PPIs and CCBs, and fewer steroids than patients in the study by Hromadkova et al. Iudici et al. (2015) examined beliefs about glucocorticoids (GCs) and adherence to GCs in Italian SSc patients. The majority of their 98 patients (83.6%) perceived GCs as necessary for symptom and disease control. This is in accordance with our study, in which 92.4% of patients displayed a high necessity score for SSc treatment (including GCs). Moreover, 72.8% of their patients had high concerns, in contrast to 54.5% in our study. We found a higher proportion of accepting and indifferent people (both low concern groups) and a lower proportion of ambivalent and sceptical patients (both high concern groups). The relatively higher necessity and lower concerns in our study compared with that of Iudici et al. (2015) might have be due to a lower number of GC users in our patients, as a lot of patients fear GCs. In contrast to our study, Iudici et al. had a high proportion of adherent patients (64.1%), assessed by the Morisky Medication Adherence Scale 4-item (MMAS-4) questionnaire. The MMAS-4 has low psychometric properties and low specificity (44%) in antihypertension validation (Lam & Fresco, 2015) and no validation in rheumatology.
A systematic review of treatment adherence in rheumatic diseases demonstrated a large variability in adherence levels in rheumatology (Harrold & Andrade, 2009) , probably owing to the differences in defining and measuring treatment adherence in the single studies. (Reach, 2011) .
Explaining low adherence rates in SSc is difficult due to the lack of studies in this field. Hromadkova et al. (2012) stated that the treatment for SSc is less potent and has less of an influence on the disease course than in RA. In addition, medication for SSc is mostly administered orally rather than by injection, such as in RA or spondyloarthritis.
Intravenous administration is less prone to poor adherence. Moreover, SSc is characterized by quiescent phases and periods of limited symptoms, which can reduce the treatment adherence.
The CQR has frequently been used in treatment adherence studies but some of these studies applied the total summed CQR score (De Thurah, Nørgaard, Harder, & Stengaard-Pedersen, 2010; Garcia-Gonzalez et al., 2008; Hromadkova et al., 2012; Xia et al., 2016) and not the weighted CQR score. We calculated both the weighted and summed CQR score. A mismatch between both scores (one <80 or <80% and one >80 or >80%) was seen in 39 patients (59.1%). One patient with a continuous score of 100 had a weighted score below 80%. Based on the continuous score, 56.1% of patients were adherent; based on the weighted score, only 28.8% were adherent.
The study had several strengths. We used the weighted CQR score, validated against the golden standard and found to predict adherence adequately, and not the total summed CQR score. Furthermore, we eliminated uncompleted CQR questionnaires, in contrast to other studies, substituting missing items with the average of nonmissing items (Zwikker et al., 2014) . This method is discouraged by the CQR developing authors (de Klerk et al., 2003) . We also emphasized psychological factors that influence adherence.
Our study also had several limitations. Firstly, our sample size (66 patients) was small, making it hard to find significant correlations.
Although SSc is an infrequent disease, a larger number of participating patients would be recommended in further research. Secondly, we asked about all prescribed medications, without making a distinction between different medication groups. A drug-specific measurement of adherence could be applied in further research. Furthermore, we used a cross-sectional study design, which creates a snapshot, rather than following adherence and treatment changes over time. Finally, the CQR has been validated in RA, polymyalgia rheumatica and gout, but not in SSc. All of these rheumatic diseases have a different course, prognosis, patient population and treatment, raising the question of whether the CQR is an appropriate questionnaire for assessing treatment adherence in SSc patients.
| CONCLUSION
To our knowledge, this is the first study in Western European patients aimed at assessing treatment adherence in SSc, and the factors influencing this adherence. We found a low adherence rate in SSc patients. We could not find a demographic, clinical or psychological factor that was significantly correlated with adherence, except for the IPQ-R variable "timeline acute/chronic". This reflects a correlation between poor adherence and the belief that SSc will last a long time and will not improve. SSc patients are convinced about the necessity of their treatment but they also have, to a lesser degree, concerns. This high necessity was not correlated with better treatment adherence.
When using the CQR to determine treatment adherence, it is recommended that the weighted score is calculated.
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